» Articles » PMID: 38399468

Innovative Approach to Producing Palladium-103 for Auger-Emitting Radionuclide Therapy: A Proof-of-Concept Study

Overview
Publisher MDPI
Specialty Chemistry
Date 2024 Feb 24
PMID 38399468
Authors
Affiliations
Soon will be listed here.
Abstract

Auger-emitting radionuclides, exemplified by Pd-103, exhibit considerable therapeutic potential in cancer treatment due to their high cytotoxicity and localized biological impact. Despite these advantages, the separation of such radionuclides presents a complicated challenge, requiring intricate and time-intensive "wet chemistry" methods attributed to the exceptional chemical inertness of the associated metals. This study proposes an innovative solution to this separation challenge through the design and implementation of a piece of radionuclide separation equipment (RSE). The equipment employs a dry distillation approach, capitalizing on differences in partial vapor pressures between irradiated and resulting radioactive metals, with a diffusion-driven extraction method applied to separate Pd-103 radionuclides generated via the proton irradiation of Rh-103 at cyclotron. Our optimization endeavors focused on determining the optimal temperature for effective metal separation and adjusting the diffusion, evaporation, and deposition rates, as well as addressing chemical impurities. The calculations indicate 17% ± 2% separation efficiency with our RSE. Approximately 77 ± 2% and 49 ± 2% of the deposited Pd-103 were isolated on substrates of Nb foil and ZnO-covered W disc, respectively. The proposed innovative dry distillation method that has been experimentally tested offers a promising alternative to conventional separation techniques, enabling enhanced purity and cost-efficient cancer treatment strategies.

Citing Articles

Palladium-103 (Pd/Rh), a promising Auger-electron emitter for targeted radionuclide therapy of disseminated tumor cells - absorbed doses in single cells and clusters, with comparison to Lu and Tb.

Hindie E, Larouze A, Alcocer-Avila M, Morgat C, Champion C Theranostics. 2024; 14(11):4318-4330.

PMID: 39113794 PMC: 11303077. DOI: 10.7150/thno.95436.

References
1.
Pirovano G, Wilson T, Reiner T . Auger: The future of precision medicine. Nucl Med Biol. 2021; 96-97:50-53. PMC: 8164972. DOI: 10.1016/j.nucmedbio.2021.03.002. View

2.
Pomplun E, Terrissol M . Low-energy electrons inside active DNA models: a tool to elucidate the radiation action mechanisms. Radiat Environ Biophys. 1994; 33(4):279-92. DOI: 10.1007/BF01210450. View

3.
Ku A, Facca V, Cai Z, Reilly R . Auger electrons for cancer therapy - a review. EJNMMI Radiopharm Chem. 2019; 4(1):27. PMC: 6800417. DOI: 10.1186/s41181-019-0075-2. View

4.
Sudar S, Cserpak F, Qaim S . Measurements and nuclear model calculations on proton-induced reactions on 103Rh up to 40 MeV: evaluation of the excitation function of the 103Rh(p,n)103Pd reaction relevant to the production of the therapeutic radionuclide 103Pd. Appl Radiat Isot. 2002; 56(6):821-31. DOI: 10.1016/s0969-8043(02)00054-4. View

5.
Tavares A, R S Tavares J . (99m)Tc Auger electrons for targeted tumour therapy: a review. Int J Radiat Biol. 2010; 86(4):261-70. DOI: 10.3109/09553000903564083. View